2nd Next Gen Lipid-Based Nanoparticles Delivery

Memo

2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit returns to unite 140+ biopharma thought leaders in the field all racing to uncover the potential of lipid-delivery properties. This is your definitive industry-led meeting to discover new lipid-based nanoparticle formulations and engineer delivery systems for emerging payloads beyond RNA for extrahepatic delivery. Providing a complete picture of the lipid-based delivery landscape, from liposomes to LNPs, polymeric lipid nanoparticles, lipid nano-crystals and beyond, join market-leaders to progress your candidates to the clinic applying translatability insights to safeguard payload safety and efficacy. Join AstraZeneca, Beam Therapeutics, Genentech, BMS and more to expedite the next-generation of lipid-based nanoparticle delivery systems closer to patients this August! Group discounts and early booking rates are available. Please visit the website for full pricing information. URLs:Tickets: https://go.evvnt.com/1646717-2?pid=5569 Brochure: https://go.evvnt.com/1646717-3?pid=5569  Date and Time: On Tue, 29 Aug 2023 09:00 - Thu, 31 Aug 2023 16:45 Venue details: Boston Park Plaza, 50 Park Plaza, Boston, Massachusetts, 02116, United States Prices:Conference + 3 Workshops - Drug Developer Pricing: USD 5046.00,Conference + 2 Workshops - Drug Developer Pricing: USD 4397.00,Conference + 1 Workshop - Drug Developer Pricing: USD 3748.00,Conference Only - Drug Developer Pricing: USD 3099.00,Conference + 3 Workshops - Solution Provider Pricing: USD 5946.00,Conference + 2 Workshops - Solution Provider Pricing: USD 5197.00,Conference + 1 Workshop - Solution Provider Pricing: USD 4448.00,Conference Only - Solution Provider Pricing: USD 3699.00 Speakers: Ami Jo, Senior Process Engineer, Drug Product Process Development, Omega Therapeutics, Badri Ananthanarayanan, Head of Delivery, EARLI, Bei Cheng, Senior Scientist, AstraZeneca, Daniel Anderson, Professor of Chemical Engineering and Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Devyn Smith, Chief Executive Officer, Arbor Biotech, Gaurav Sahay, Associate Professor, Oregan State University, Gulen Yesilbag Tonga, Senior Scientist, Delivery Sciences, Tessera Therapeutics, Haishan Li, Director, Chemistry and Process Development, Hopewell Therapeutics Inc., Hideyoshi Harashima, Professor of Pharmaceutics and the chair of the Laboratory of Molecular Design of Pharmaceutics, Faculty of Pharmaceutical | Hokkaido University, James Ferguson, Chief Medical Officer, Matinas BioPharma, Jeffrey Clogston, Principal Scientist, Physiochemical Characterization Section Head Nanotechnology Characterization, Laboratory, National Cancer Institute, Leidos Biomedical Research, Julie Shi, Associate Director - Scientific, Process Research and Engineering, Bristol Myers Squibb, Justin Cohen, Director, Molecular Discovery, Analytical Conjugation Sciences, Pfizer, Manmohan Singh, Chief Technology Officer, Beam Therapeutics, Mansoor Amiji, University Distinguished Professor, Northeastern University, Manuel Sanchez-Felix, Senior Fellow, Novel Delivery Technologies, Novartis, Niren Murthy, Professor, Department of Bioengineering, University of California, Berkeley, Saikat Manna, Senior Scientist, Delivery and Formulation, Sanofi U.S., Shashi Murthy, Co-Founder and Chief Technology, Officer Nanite, Sriram Sathyanarayanan, Chief Scientific Officer, Codiak Biosciences, Stephan Stern, Laboratory Co-Director, Director of Research and Development, Nanotechnology Characterization Laboratory, National Cancer Institute, Suzanne Saffie-Siebert, Chairwoman and Chief Executive Officer, SiSaf LTD, Theodore Ashburn, President and Chief Executive Officer, Oncorus, Vicent Nebot, Chief Technology Officer and Head of EU, Curapath, Whitney Shatz-Binder, Principal Scientist, Genentech, Yashwant Pathak, Associate Dean Faculty Affairs, University of South Florida